Plasminogen activator inhibitor-1 4G/5G polymorphism and susceptibility to endometriosis in the Italian population

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objectives: Some controversy exists for the potential association of the plasminogen activator inhibitor-1 (PAI-1) gene polymorphism 4G/5G and susceptibility to endometriosis. To clarify this issue, we have examined the prevalence of this polymorphism in a case-control study in the Italian population. Study design: The PAI-1 4G/5G polymorphism was evaluated in n = 368 reproductive year aged Caucasian women who underwent gynaecological laparoscopy for chronic pelvic pain, infertility, ovarian cysts and myomas. A second group of controls included n = 329 normal subjects. Results: The 697 women enrolled were divided as follows: the endometriosis group (n = 204), the gynaecological control group (n = 164) and the general population control group (n = 329). No statistical significant differences emerged between endometriosis patients and gynaecological controls with regard to the allele frequencies and co-dominant and dominant models of genotype distribution. A borderline statistical difference was only observed for the recessive model of inheritance in which, contrary to previous findings, the PAI-1 4G/4G genotype seems to be less linked to the disease development. Conclusion: The findings reported herein do not support the previously reported data indicating a greater susceptibility to endometriosis in patients harbouring the PAI-1 4G/5G and 4G/4G genotypes and exclude a significant role of polymorphism in endometriosis development.

Original languageEnglish
Pages (from-to)219-221
Number of pages3
JournalEuropean Journal of Obstetrics and Gynecology and Reproductive Biology
Volume146
Issue number2
DOIs
Publication statusPublished - Oct 2009

Fingerprint

Plasminogen Activator Inhibitor 1
Endometriosis
Population
Genotype
Control Groups
Myoma
Ovarian Cysts
Pelvic Pain
Population Control
Population Groups
Gene Frequency
Chronic Pain
Laparoscopy
Infertility
Case-Control Studies
Genes

Keywords

  • Endometriosis
  • Plasminogen activator inhibitor-1
  • Polymorphism

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

@article{6106cb55d25840578e0b5e5206f7258a,
title = "Plasminogen activator inhibitor-1 4G/5G polymorphism and susceptibility to endometriosis in the Italian population",
abstract = "Objectives: Some controversy exists for the potential association of the plasminogen activator inhibitor-1 (PAI-1) gene polymorphism 4G/5G and susceptibility to endometriosis. To clarify this issue, we have examined the prevalence of this polymorphism in a case-control study in the Italian population. Study design: The PAI-1 4G/5G polymorphism was evaluated in n = 368 reproductive year aged Caucasian women who underwent gynaecological laparoscopy for chronic pelvic pain, infertility, ovarian cysts and myomas. A second group of controls included n = 329 normal subjects. Results: The 697 women enrolled were divided as follows: the endometriosis group (n = 204), the gynaecological control group (n = 164) and the general population control group (n = 329). No statistical significant differences emerged between endometriosis patients and gynaecological controls with regard to the allele frequencies and co-dominant and dominant models of genotype distribution. A borderline statistical difference was only observed for the recessive model of inheritance in which, contrary to previous findings, the PAI-1 4G/4G genotype seems to be less linked to the disease development. Conclusion: The findings reported herein do not support the previously reported data indicating a greater susceptibility to endometriosis in patients harbouring the PAI-1 4G/5G and 4G/4G genotypes and exclude a significant role of polymorphism in endometriosis development.",
keywords = "Endometriosis, Plasminogen activator inhibitor-1, Polymorphism",
author = "Davide Gentilini and Paola Vigano and Davide Castaldi and Daniela Mari and Mauro Busacca and Paolo Vercellini and Edgardo Somigliana and {di Blasio}, {Anna Maria}",
year = "2009",
month = "10",
doi = "10.1016/j.ejogrb.2009.06.008",
language = "English",
volume = "146",
pages = "219--221",
journal = "European Journal of Obstetrics, Gynecology and Reproductive Biology",
issn = "0028-2243",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Plasminogen activator inhibitor-1 4G/5G polymorphism and susceptibility to endometriosis in the Italian population

AU - Gentilini, Davide

AU - Vigano, Paola

AU - Castaldi, Davide

AU - Mari, Daniela

AU - Busacca, Mauro

AU - Vercellini, Paolo

AU - Somigliana, Edgardo

AU - di Blasio, Anna Maria

PY - 2009/10

Y1 - 2009/10

N2 - Objectives: Some controversy exists for the potential association of the plasminogen activator inhibitor-1 (PAI-1) gene polymorphism 4G/5G and susceptibility to endometriosis. To clarify this issue, we have examined the prevalence of this polymorphism in a case-control study in the Italian population. Study design: The PAI-1 4G/5G polymorphism was evaluated in n = 368 reproductive year aged Caucasian women who underwent gynaecological laparoscopy for chronic pelvic pain, infertility, ovarian cysts and myomas. A second group of controls included n = 329 normal subjects. Results: The 697 women enrolled were divided as follows: the endometriosis group (n = 204), the gynaecological control group (n = 164) and the general population control group (n = 329). No statistical significant differences emerged between endometriosis patients and gynaecological controls with regard to the allele frequencies and co-dominant and dominant models of genotype distribution. A borderline statistical difference was only observed for the recessive model of inheritance in which, contrary to previous findings, the PAI-1 4G/4G genotype seems to be less linked to the disease development. Conclusion: The findings reported herein do not support the previously reported data indicating a greater susceptibility to endometriosis in patients harbouring the PAI-1 4G/5G and 4G/4G genotypes and exclude a significant role of polymorphism in endometriosis development.

AB - Objectives: Some controversy exists for the potential association of the plasminogen activator inhibitor-1 (PAI-1) gene polymorphism 4G/5G and susceptibility to endometriosis. To clarify this issue, we have examined the prevalence of this polymorphism in a case-control study in the Italian population. Study design: The PAI-1 4G/5G polymorphism was evaluated in n = 368 reproductive year aged Caucasian women who underwent gynaecological laparoscopy for chronic pelvic pain, infertility, ovarian cysts and myomas. A second group of controls included n = 329 normal subjects. Results: The 697 women enrolled were divided as follows: the endometriosis group (n = 204), the gynaecological control group (n = 164) and the general population control group (n = 329). No statistical significant differences emerged between endometriosis patients and gynaecological controls with regard to the allele frequencies and co-dominant and dominant models of genotype distribution. A borderline statistical difference was only observed for the recessive model of inheritance in which, contrary to previous findings, the PAI-1 4G/4G genotype seems to be less linked to the disease development. Conclusion: The findings reported herein do not support the previously reported data indicating a greater susceptibility to endometriosis in patients harbouring the PAI-1 4G/5G and 4G/4G genotypes and exclude a significant role of polymorphism in endometriosis development.

KW - Endometriosis

KW - Plasminogen activator inhibitor-1

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=70349623910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349623910&partnerID=8YFLogxK

U2 - 10.1016/j.ejogrb.2009.06.008

DO - 10.1016/j.ejogrb.2009.06.008

M3 - Article

C2 - 19608328

AN - SCOPUS:70349623910

VL - 146

SP - 219

EP - 221

JO - European Journal of Obstetrics, Gynecology and Reproductive Biology

JF - European Journal of Obstetrics, Gynecology and Reproductive Biology

SN - 0028-2243

IS - 2

ER -